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current skin deterioration in patients suffering from 
moderate or severe psoriasis vulgaris underline the neces-
sity for innovative, long-lasting therapies with few 
side-effects.
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LIFE
Taïeb C, Marionneau N, Myon E
Pharmaco Economics & Quality of Life Department,
Boulogne Billancourt, France
Quality of life questionnaires enable patients to express
their personal evaluation of the consequences of their
condition and/or treatment. Psoriasis has a heavy impact
on the physical and mental well-being of the patient.
OBJECTIVE: To evaluate the impact of the duration of
psoriasis on the quality of life of patients. METHOD:
Within the context of the SPOT study, 668 patients
(newly diagnosed patients: n = 319, Patients followed for
longer than 5 years: n = 347) responded to a quality of
life questionnaire consisting of a generic scale (SF-12) and
a speciﬁc scale (PDI–Psoriasis Disability Index). The com-
pleted questionnaires were returned in prepaid envelopes.
RESULTS: The socio-demographic proﬁle of the patients
in the two groups did not present any statistically signif-
icant difference (place of residence, lifestyle). The mean
age was respectively 42.9 years for newly diagnosed
patients versus 48.1 years for patients who had been fol-
lowed for longer than 5 years. The PDI score was 10.7%
(SD = 11.7) for newly diagnosed patients and 15.7% (SD
= 13.5) for patients that had been followed for longer
than 5 years (p < 0.0001). With regard to the SF-12, the
results were organised in 2 scores: mental (MCS-12) and
physical (PCS-12). The scores for newly diagnosed
patients were: PCS-12 = 52.4 (SD = 7.1) & MCS-12 =
42.8 (SD = 10.5) the scores for the Patients followed for
longer than 5 years were: PCS-12 = 50.6 (SD = 8.0) &
MCS-12 = 41.0 (SD = 10.7). The differences observed in
the two dimensions, physical and mental, were statisti-
cally signiﬁcant (p = 0.0038 and p = 0.0281). CON-
CLUSION: These results show a quality of life’s
impairing for the population that had been followed for
longer than 5 years, a difference conﬁrmed by both the
speciﬁc and generic scales.
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Psoriasis is a chronicle disease, which concerns 4.7% of
the European population. Even if it does not question the
vital prognosis, it is a very invalidating condition in daily
life because of the damage to the body image. Therefore
the patients’ quality of life improvement is one of the
medical treatment’s priority. OBJECTIVE: To assess the
impact of a medical strategy on patients’ quality of life.
METHOD: SPOT is a longitudinal, prospective observa-
tional program following 400 psoriasis patients in Spain
The Psoriasis Disability Index (Pr Finlay, 1987) and the
SF12 are evaluated, the completed questionnaires were
returned by post. RESULTS: In this ﬁrst analysis, the ﬁrst
74 patients were taken into account and analysed at inclu-
sion and 3 months after the treatment initiation. The PDI
score at inclusion is 11.88 (sd = 10). The PDI score 3
months after is 8.88 (sd = 9.48). These ﬁrst results show
evidence of an improvement of patients’ quality of life 3
months after treatments (p < 0.02). Concerning the SF-
12, the results consisted of two scores: mental (MCS-12)
and physical (PCS-12). At inclusion the SF12 scores were:
PCS-12 = 50 (sd = 8) & MCS-12 = 49.9 (sd = 9.8), 3
months after the scores were the following PCS-12 = 52
(sd = 7.6) & MCS-12 = 50.7 (sd:7.6). The improvement
of the quality of life in their physical health dimension is
statistically signiﬁcant (p < 0.03). CONCLUSION: Con-
cerning the PDI, the following dimensions “daily activi-
ties, leisure and social relations” are signiﬁcantly
improved (p < 0.02), which might have consequences on
patients’ daily life.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. The large number of
quality of life studies that exist conﬁrms this. OBJEC-
TIVES: To evaluate the effect of psoriasis on quality of
life of patients in Spain. METHOD: A total of 4500
anonymous questionnaires (comprised of two scales: the
Psoriasis Disability Index (PDI) plus 10 questions con-
cerning treatment and evolution of psoriasis) were sent,
via a Psoriasis Patient Support Group (AccionPsoriasis).
RESULTS: A total of 1900 questionnaires were returned
(June 2002): response rate 42%. An analysis of the ﬁrst
810 questionnaires was realised. The sex ratio Men
(M)/Women(W) was: 49/51. Mean age: 42 years. Mean
age of diagnosis: 21.8 years. The average to the total score
was 8.47 (s.d. 7.2 rank 0 to 39) i.e. 18.82 (s.d.: 17.2)
when reported to a scale of 0 to 100. Signiﬁcant differ-
ence was observed between M and W for the global 
handicap score 20.73 vs 16.95 p < 0.002. Two groups
was identiﬁed: pousée de psoriasis (84%), pas de poussée
de psorisis (12%)—no answers (4%). Psoriasis had a
greater adverse affect on patients with crise: PDI score =
20.24 (sd 17.52) than the patient without actual crise 
PDI score = 8.98 (sd 11.34). This difference was signi-
ﬁcative p < 0.00001. CONCLUSION: These results high-
light the value of appropriate and relevant psychological
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and medical environment for patient suffering from 
psoriasis.
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Psoriasis has a heavy impact on the physical and mental
well-being of the patient, especially when the areas
affected are visible to others. Do women affected by pso-
riasis suffer more than men in this respect? OBJECTIVE:
To evaluate the quality of life level of patients with 
psoriasis according to gender. METHOD: Within the
context of the SPOT study, 542 patients (298 men/244
women) responded to a qol questionnaire consisting of a
generic scale (SF-12) and a speciﬁc scale (PDI–Psoriasis
Disability Index). The completed questionnaires were
returned in prepaid envelopes. RESULTS: The socio-
demographic proﬁle of the patients in the two groups did
not present any statistically signiﬁcant difference The
mean age was respectively 46.3 years for the men versus
44.6 years for the women. The PDI score was 11.9% (SD
= 11.7) for the men and 14.8% (SD = 14.4) for the
women; the difference was statistically signiﬁcant (p =
0.031). For the Work, Social relations, Leisure and Treat-
ment dimensions, no difference was observed between the
two sexes: respectively 6.8% (SD = 13.6), 13.0% (SD =
19.4), 12.5% (SD = 16.5), 11.6% (SD = 18.2) in men
versus 7.9% (SD = 15.2), 14.7% (SD = 23.1), 14.1% 
(SD = 18.2), 11.8% (SD = 20.6) in women. On the other
hand, for the Daily Activities dimension the score was
14.0% (SD = 13.3) for the men and 19.9% (SD = 18.4)
for the women. The difference was statistically signiﬁcant
(p < 0.0007). With regard to the SF-12, the results were
organised in 2 scores: mental (MCS-12) and physical
(PCS-12). The scores for the men were: PCS-12 = 51.3
(SD = 7.6) & MCS-12 = 43.4 (SD = 10.0). The scores 
for the women were: PCS-12 = 51.6 (SD = 7.9) & 
MCS-12 = 40.1 (SD = 11.3). With regard to the mental
dimension, the difference was statistically signiﬁcant 
(p < 0.0005). CONCLUSION: Psoriasis modiﬁes the
quality of life more greatly for women, who suffer more
than men. This is especially true for the mental dimen-
sion (SF12) and for the daily activities dimension as
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By deﬁnition, dermatological pathologies have an effect
on one’s self-image, and this may lead to severe psycho-
logical troubles. OBJECTIVES: To evaluate depressive
symptomatology–DS-in patients suffering from chronic
dermatosis. To evaluate the effect of chronic dermatosis
on depressive symptomatology in France for patients
going to a medical consultation at Saint Louis Hospital
(Paris—France). METHODS: The CES-D was remitted to
every patients entering any dermatological consulting
room at Saint Louis Hospital. Two groups were identi-
ﬁed: population coming to a speciﬁc and thematic
doctor’s visit (psoriasis, atopic dermatitis, . . .)—usual
visits or patients coming to the “consultation porte”
(doctor visits without any appointment and taking care
of more distressed dermatological diseases). RESULTS:
The “consultation porte” represents around 22% of the
doctor’s visits versus 78% for the usual visits visits. In 
the studied population (n = 774), 23.6% of the patients
reported depressive symptomatology (CES-D+) whereas
76.4% did not (CES-D-). For patients coming to the
“consultation porte” CES-D+ population represents
31.4% (n = 172) vs 21.4% in the patients having usual
visit (n = 602). As shown, depressive symptomatology is
more often reported for patient coming to the “consulta-
tion porte” compared to patients coming to the usual
visits. This difference is statistically signiﬁcant (test Chi 2
p < 0.01). If we compare the depressive symptomatology
incidence according to dermatological disease, the results
are the following: psoriasis 19%, atopic Dermatitis 28%,
acne 32, and nævi 13%. CONCLUSION: These results
thus give us an idea of both the extent and the impor-
tance of the psychological impact that dermatological 
diseases usually generate. Global disease management
together with psychological support therefore seems
essential for patients suffering from chronic dermatosis.
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OBJECTIVES: To assess the impact of psoriasis vulgaris
treatment with tacalcitol on quality of life. METHODS:
An epidemiological, observational, prospective and mul-
ticenter study of a cohort of patients with mild to mod-
erate Psoriasis vulgaris has been performed. Patients have
been treated with tacalcitol ointment (4mg/g). Anthro-
pometric and demographic characteristics of patients
were recorded in addition to percentage of affected area
and previous and current treatments. Symptomatology
(erythema, desquamation and thickness) was evaluated
by a scale from 0 (absent) to 4 (maximum intensity of
symptom). At follow-up (15 and 60 days) symptomatol-
ogy and appearance of adverse effects were registered.
